2026-01-22 - Analysis Report
# Financial Report for Abbott Labs (ABT)

## 1. Return Rate Analysis
- **Cumulative return of Abbott Labs**: 31.42%
- **Cumulative return of S&P 500 (VOO)**: 91.55%
- **Divergence**: -60.80%

**Analysis**: Abbott Labs has significantly underperformed compared to the S&P 500, with a divergence of -60.80%. This indicates a substantial lag in cumulative returns relative to the benchmark.

### Alpha, Beta Analysis
| Year       | CAGR  | MDD   | Alpha | Beta  | Cap(B)  |
|------------|-------|-------|-------|-------|---------|
| 2016-2018  | 32.0% | 14.5% | 28.0% | 1.1   | 125.9   |
| 2017-2019  | 41.0% | 14.5% | 24.0% | 1.0   | 151.2   |
| 2018-2020  | -1.0% | 16.8% | -22.0%| 0.9   | 190.6   |
| 2019-2021  | 42.0% | 16.8% | -2.0% | 0.8   | 244.9   |
| 2020-2022  | -20.0%| 28.8% | -18.0%| 0.8   | 191.1   |
| 2021-2023  | -22.0%| 28.8% | -23.0%| 0.7   | 191.6   |
| 2022-2024  | -31.0%| 24.3% | -50.0%| 0.7   | 196.9   |
| 2023-2025  | 10.0% | 16.0% | -52.0%| 0.3   | 218.1   |

**Analysis**: The data shows fluctuating performance, with periods of high growth (CAGR of 42.0%) contrasted by significant downturns (CAGR of -31.0%). The Alpha values indicate varying levels of outperformance against the benchmark.

---

## 2. Recent Stock Price Fluctuations
- **Current Price**: $120.73
- **Previous Close**: $121.14
- **Price Change**: -$0.34
- **5-day SMA**: $122.43
- **20-day SMA**: $124.68
- **60-day SMA**: $125.71

**Analysis**: The stock price has shown a slight decline from the previous close, with moving averages indicating a downward trend over the past 5, 20, and 60 days.

---

## 3. RSI and PPO Analysis
- **Market Risk Indicator (MRI)**: 0.80 (Medium Investment)
- **RSI**: 31.47 (Indicating oversold conditions)
- **PPO**: -0.41
- **Expected Return**: -1605.30%

**Analysis**: The RSI suggests the stock is oversold, while the PPO indicates negative momentum. The expected return is extremely negative, implying a substantial risk if held long-term.

---

## 4. Recent News & Significant Events
- **Headlines**:
  - Abbott Laboratories stock position lifted by Vest Financial LLC.
  - Analysis on Abbott's pricing relative to its medical device and diagnostics momentum.
  - Q4 2025 earnings preview.
  - Wall Street analysts consider Abbott a good investment.
  - Comparison between PBH and ABT for better value.
  - Q4 earnings report preview: what to look for.

**Analysis**: The news indicates mixed sentiments on Abbott Labs, with some analysts expressing confidence in the stock while others raise concerns about its valuation and earnings potential.

---

## 4-2. Analyst Opinions
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.76 (~Buy)
- Opinions: 25
- Target Price (avg/high/low): 144.75 / 169.00 / 122.00
```

---

## 5. Recent Earnings Analysis
| Date       | EPS  | Revenue  |
|------------|------|----------|
| 2025-10-29 | 0.94 | 11.37 B$ |
| 2025-07-30 | 1.02 | 11.14 B$ |
| 2025-04-30 | 0.76 | 10.36 B$ |
| 2024-10-31 | 0.94 | 10.63 B$ |
| 2025-10-29 | 0.94 | 10.63 B$ |

**Analysis**: The earnings per share (EPS) and revenue figures reflect a stable performance with some fluctuations. The highest revenue recorded was $11.37B.

---

## 6. Financial Information
### Revenue and Profitability
| Quarter     | Revenue | Profit Margin |
|-------------|---------|---------------|
| 2025-09-30  | $11.37B | 55.36%        |
| 2025-06-30  | $11.14B | 56.44%        |
| 2025-03-31  | $10.36B | 56.86%        |
| 2024-12-31  | $10.97B | 54.97%        |
| 2024-09-30  | $10.63B | 55.83%        |

### Capital and Profitability
| Quarter     | Equity  | ROE  |
|-------------|---------|------|
| 2025-09-30  | $50.95B | 3.23%|
| 2025-06-30  | $50.56B | 3.52%|
| 2025-03-31  | $48.81B | 2.71%|
| 2024-12-31  | $47.66B | 19.36%|
| 2024-09-30  | $39.80B | 4.14%|

**Analysis**: Revenue is relatively stable, though profit margins indicate slight fluctuations. The ROE shows significant variation, particularly with a peak of 19.36% in late 2024.

---

## 7. Comprehensive Analysis
Abbott Labs has demonstrated inconsistent performance metrics compared to the S&P 500, with a current divergence of -60.80%. Recent price movements show a downward trend, and indicators such as RSI and PPO suggest a challenging market position. Despite a largely favorable analyst consensus, the earnings and financial data highlight some volatility and risk, with medium investment levels recommended due to the current market risk indicator.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.